Clinical-stage immuno-oncology company BriaCell Therapeutics (TSX:BCT,NASDAQ:BCTX) has achieved a “key genetic engineering milestone” with ‘Melanoma’, its personalized whole-cell melanoma immunotherapy vaccine candidate.The achievement allows the vaccine’s program to proceed towards clinical development, catching the eye of healthcare publication Inside Precision Medicine.In an article, Inside Precision…
Investing
Connect with us Information About UsContact UsCareersPartnerships Advertise With Us AuthorsBrowse TopicsEventsDisclaimerPrivacy Policy Australia North America World LoginInvesting News NetworkYour trusted source for investing…
Meagen moved to Vancouver in 2019 after splitting her time between Australia…
Giann Liguid is a graduate of Ateneo De Manila University with an…
Giann Liguid is a graduate of Ateneo De Manila University with an…
Alternative Investment
